Jeffrey Ryan Stewart net worth and biography

Jeffrey Stewart Biography and Net Worth

EVP of AbbVie
Jeffrey R. Stewart is Executive Vice President, Chief Commercial Officer. He is responsible for leading the largest commercial area for the enterprise encompassing multiple therapeutic areas across immunology, oncology, virology, eye care, neuroscience, endo-metabolics, gastroenterology, specialty products and women’s health.

Mr. Stewart joined Abbott in 1992 as part of TAP, Abbott’s former U.S. joint venture with Takeda Chemical Industries. Following his time with TAP, Mr. Stewart held various leadership positions in Abbott’s U.S. and international pharmaceutical businesses, including Divisional Vice President, Immunology; Divisional Vice President, Primary Care; General Manager, Virology; and General Manager, United Kingdom. Prior to AbbVie's separation from Abbott in January 2013, Mr. Stewart served as Vice President, Abbott Proprietary Pharmaceutical Division, United States.

Mr. Stewart previously led the U.S. Area for 10 years, including most recently as Senior Vice President, U.S. Commercial Operations.
Mr. Stewart previously served on the Board of the National Pharmaceutical Council and serves on the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). At AbbVie, he is the executive chair of the PRIDE Employee Resource Group.

What is Jeffrey Ryan Stewart's net worth?

The estimated net worth of Jeffrey Ryan Stewart is at least $10.23 million as of December 29th, 2020. Mr. Stewart owns 76,259 shares of AbbVie stock worth more than $10,234,720 as of October 1st. This net worth approximation does not reflect any other assets that Mr. Stewart may own. Additionally, Mr. Stewart receives an annual salary of $3,250,000.00 as EVP at AbbVie. Learn More about Jeffrey Ryan Stewart's net worth.

How old is Jeffrey Ryan Stewart?

Mr. Stewart is currently 53 years old. There are 8 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 68 years old. Learn More on Jeffrey Ryan Stewart's age.

What is Jeffrey Ryan Stewart's salary?

As the EVP of AbbVie Inc., Mr. Stewart earns $3,250,000.00 per year. There are 3 executives that earn more than Mr. Stewart. The highest earning executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who commands a salary of $7,420,000.00 per year. Learn More on Jeffrey Ryan Stewart's salary.

How do I contact Jeffrey Ryan Stewart?

The corporate mailing address for Mr. Stewart and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Jeffrey Ryan Stewart's contact information.

Has Jeffrey Ryan Stewart been buying or selling shares of AbbVie?

Jeffrey Ryan Stewart has not been actively trading shares of AbbVie during the last ninety days. Most recently, Jeffrey Ryan Stewart sold 27,690 shares of the business's stock in a transaction on Thursday, March 24th. The shares were sold at an average price of $159.20, for a transaction totalling $4,408,248.00. Learn More on Jeffrey Ryan Stewart's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 17 times. They sold a total of 1,048,944 shares worth more than $146,558,841.47. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Jeffrey Ryan Stewart Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/24/2022Sell27,690$159.20$4,408,248.00View SEC Filing Icon  
12/15/2021Sell2,152$128.00$275,456.00View SEC Filing Icon  
12/29/2020Sell25,290$105.00$2,655,450.0076,259View SEC Filing Icon  
5/12/2020Sell23,024$90.00$2,072,160.0052,760View SEC Filing Icon  
8/16/2019Buy15,552$64.44$1,002,170.8865,304View SEC Filing Icon  
See Full Table

Jeffrey Ryan Stewart Buying and Selling Activity at AbbVie

This chart shows Jeffrey Ryan Stewart's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $134.21
Low: $134.09
High: $142.33

50 Day Range

MA: $141.00
Low: $134.21
High: $151.15

2 Week Range

Now: $134.21
Low: $106.86
High: $175.91

Volume

15,336,473 shs

Average Volume

6,873,221 shs

Market Capitalization

$237.30 billion

P/E Ratio

19.01

Dividend Yield

3.95%

Beta

0.72